1. Cirello, Valentina, Grassi, Elisa Stellaria, Pogliaghi, Gabriele, Colombo, Carla, Fugazzola, Laura. 2022. FAM83B is involved in thyroid cancer cell differentiation and migration. In Scientific reports, 12, 8608. doi:10.1038/s41598-022-12553-2. https://pubmed.ncbi.nlm.nih.gov/35597845/
2. Zhang, Jing, Wang, Jiajia, Yue, Ke, Wang, Yan, Wu, Xiaojuan. 2023. FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway. In BMC pulmonary medicine, 23, 32. doi:10.1186/s12890-022-02303-5. https://pubmed.ncbi.nlm.nih.gov/36690987/
3. Cai, Ling, Luo, Danni, Yao, Bo, Xie, Yang, Xiao, Guanghua. 2019. Systematic Analysis of Gene Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma with a Case Study of FAM83A and FAM83B. In Cancers, 11, . doi:10.3390/cancers11060886. https://pubmed.ncbi.nlm.nih.gov/31242643/
4. Okabe, Naoyuki, Ezaki, Junji, Yamaura, Takumi, Waguri, Satoshi, Suzuki, Hiroyuki. 2015. FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. In International journal of oncology, 46, 999-1006. doi:10.3892/ijo.2015.2817. https://pubmed.ncbi.nlm.nih.gov/25586059/
5. Cipriano, Rocky, Graham, James, Miskimen, Kristy L S, Stark, George R, Jackson, Mark W. 2012. FAM83B mediates EGFR- and RAS-driven oncogenic transformation. In The Journal of clinical investigation, 122, 3197-210. doi:10.1172/JCI60517. https://pubmed.ncbi.nlm.nih.gov/22886302/
6. Cipriano, R, Bryson, B L, Miskimen, K L S, Brown, H A, Jackson, M W. 2013. Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B. In Oncogene, 33, 3298-306. doi:10.1038/onc.2013.293. https://pubmed.ncbi.nlm.nih.gov/23912460/
7. Lin, Qiongyan, Chen, Hui, Zhang, Minfen, Xiong, Hanzhen, Jiang, Qingping. 2019. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway. In Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 115, 108939. doi:10.1016/j.biopha.2019.108939. https://pubmed.ncbi.nlm.nih.gov/31079003/